Variable Duration Trial as an Alternative Design for Continuous Endpoints
Pharmaceutical Statistics · 2024
DOI: 10.1002/pst.2418 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2024. Verfasst von Jitendra Ganju und 1 weiteren Autor:innen. Beteiligte Einrichtung: Ganju Clinical Trials, LLC, San Francisco, California, USA. Hauptthemen laut MEDLINE: Research Design, Endpoint Determination, Clinical Trials as Topic. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Clinical trials with continuous primary endpoints typically measure outcomes at baseline, at a fixed timepoint (denoted T min ), and at intermediate timepoints. The analysis is commonly performed using the mixed model repeated measures method. It is sometimes expected that the effect size will be larger with follow‐up longer than T min . But extending the follow‐up for all patients delays trial completion. We propose an alternative trial design and analysis method that potentially increases statistical power without extending the trial duration or increasing the sample size. We propose following the last enrolled patient until T min , with earlier enrollees having variable follow‐up durations up to a maximum of T max . The sample size at T max will be smaller than at T min , and due to staggered enrollment, data missing at T max will be missing completely at random. For analysis, we propose an alpha‐adjusted procedure based on the smaller of the p values at T min and T max , termed . This approach can provide the highest power when the powers at T min and T max are similar. If the power at T min and T max differ significantly, the power of is modestly reduced compared with the larger of the two powers. Rare disease trials, due to the limited size of the patient population, may benefit the most with this design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ganju Clinical Trials, LLC, San Francisco, California, USA.
- RemeGen Co., Ltd, Yantai, China.
ORCID-Profile: Jitendra Ganju
Zitieren
APA
Ganju, J., & Ma, J. G. (2024). Variable Duration Trial as an Alternative Design for Continuous Endpoints. Pharmaceutical Statistics. https://doi.org/10.1002/pst.2418
Vancouver
Ganju J, Ma JG. Variable Duration Trial as an Alternative Design for Continuous Endpoints. Pharmaceutical Statistics. 2024. doi:10.1002/pst.2418
BibTeX
@article{Ganju2024,
author = {Ganju, Jitendra and Ma, Julie Guoguang},
title = {Variable Duration Trial as an Alternative Design for Continuous Endpoints},
journal = {Pharmaceutical Statistics},
year = {2024},
doi = {10.1002/pst.2418}
}
EUVIMED